Active substance
Results for the substance vestronidase alfa
1 result
About this active substance
Vestronidase alfa is a recombinant enzyme used for the treatment of the lysosomal storage disorder known as mucopolysaccharidosis type VII (MPS VII), or Sly syndrome. This is a rare genetic condition caused by a deficiency of the enzyme beta-glucuronidase, leading to the accumulation of glycosaminoglycans (GAGs) in cells and tissues, which causes progressive damage.
Vestronidase alfa works by replacing the missing or deficient enzyme, helping to break down and clear the accumulated glycosaminoglycans. The treatment can reduce symptoms of the disease, such as organ damage, respiratory difficulties, and reduced mobility.
The medication is administered via intravenous infusion, typically once every two weeks, under the supervision of a specialist. Common side effects include infusion-related reactions such as fever, chills, rash, or nausea. Rarely, severe allergic reactions (anaphylaxis) may occur.
Patients should be closely monitored during treatment, and any adverse reactions or concurrent medications should be reported to the healthcare provider. Vestronidase alfa is an enzyme replacement therapy that can improve the quality of life for patients with MPS VII, but it is not a complete cure for the disease.
Vestronidase alfa works by replacing the missing or deficient enzyme, helping to break down and clear the accumulated glycosaminoglycans. The treatment can reduce symptoms of the disease, such as organ damage, respiratory difficulties, and reduced mobility.
The medication is administered via intravenous infusion, typically once every two weeks, under the supervision of a specialist. Common side effects include infusion-related reactions such as fever, chills, rash, or nausea. Rarely, severe allergic reactions (anaphylaxis) may occur.
Patients should be closely monitored during treatment, and any adverse reactions or concurrent medications should be reported to the healthcare provider. Vestronidase alfa is an enzyme replacement therapy that can improve the quality of life for patients with MPS VII, but it is not a complete cure for the disease.